LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial

Authors :: Virginie Verkarre
R. Elaidi
Diane Pannier
Denis Maillet
C-M. Sun
Marine Gross-Goupil
Catherine Sautès-Fridman
Christophe Tournigand
Florence Joly
M. Bennamoun
Gwenaelle Gravis
Christine Chevreau
W-H. Fridman
Yann-Alexandre Vano
Delphine Borchiellini
Stéphane Oudard
B. Laguerre
Philippe Barthélémy
Stefano Caruso
Jessica Zucman-Rossi
Source :: Annals of Oncology. 31:S1157
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: Oncology
VEGFR tyrosine kinase inhibitor
business.industry
Metastatic kidney cancer
Cancer research
Biomarker (medicine)
Medicine
Ipilimumab
Hematology
Nivolumab
business
medicine.drug

Full Text Access

Tools